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2 
Abstract  30 
Background – Allergic pruritus and urticaria in the horse are challenging for 31 
veterinarians and owners, and little is known about their long-term management. 32 
Objectives – To summarise intradermal allergen test results (IDT), and to assess 33 
owners’ perceptions of skin disease and of effects of medical treatment and 34 
management changes in their atopic horses over time. 35 
Animals – Eighty-two horses with atopic dermatitis in the xxx referred for IDT 36 
between 2006 and 2011. 37 
Methods – IDT results were retrospectively reviewed. Owners completed telephone 38 
questionnaires on skin changes, medication, effect of allergen-specific 39 
immunotherapy (ASIT) and management.  40 
Results- Sixty-one owners (74.4%) could be contacted, an average of 5.9 years 41 
(range 28-88 months) after IDT; of those, three could not be enrolled. Of the 58 42 
remaining horses, eleven (19%) were deceased at time of owner interview, including 43 
four (6.9%) euthanised due to uncontrollable skin disease. The remaining 47 owners 44 
reported that signs of skin disease had not been seen for at least two years in 18 45 
horses (38.3%), including two that only flared with known triggers. Twenty-nine 46 
horses (61.7%) still required medication to control skin disease although 25 (53.2%) 47 
required less since referral. Owners reported benefit from ASIT in 9/14 horses 48 
(64.3%), from glucocorticoids in 33/35 (94.3%) and from antihistamines in 17/28 49 
(60.7%). Specific management changes were implemented for 22 horses and 50 
reported as beneficial in 9/22 (40.9%).  51 
Conclusions-  Equine atopic dermatitis may not always be chronic but severe cases 52 
appear difficult to control. IDT helps to formulate ASIT and can guide management 53 
changes. 54 
 
 
 
 
3 
Introduction 55 
The management of pruritus and urticaria due to allergic skin disease in the horse is 56 
challenging for veterinary surgeons and owners, and little is known about the long-57 
term treatment requirements and progression of disease over time. 58 
In the horse, atopic dermatitis, as a hypersensitivity reaction to environmental 59 
allergens and food, presents with pruritus or urticaria or both.1-8 It is typically 60 
described as a lifelong condition requiring ongoing treatment interventions, but signs 61 
may be seasonal or perennial, depending on the causal allergens.9 Allergens 62 
commonly implicated in many reports include house dust and storage mites, insects, 63 
pollens and epithelia.6 As for other veterinary species, the diagnosis of equine atopic 64 
dermatitis is a clinical diagnosis based on compatible history, clinical signs and 65 
exclusion of other differential diagnoses such as ectoparasite infestations, Culicoides 66 
hypersensitivity and other insect bite hypersensitivities (IBH), and if possible adverse 67 
food reactions.  68 
Management strategies include allergen avoidance, topical therapy, and systemic 69 
medications such as antihistamines, glucocorticoids and tricyclic antidepressants.9 70 
Dust and moulds can be found in high concentrations in various feeds and bedding 71 
materials10 and implementation of allergen reduction measures has been shown to 72 
be beneficial in some equine patients with recurrent airway disease11,12 and in 18 of 73 
19 horses with non-summer seasonal and perennial pruritus with or without 74 
urticaria.13 Many topical therapies are likely used but there is little published evidence 75 
regarding their use or efficacy. Hydrocortisone aceponate spray (Cortavance, Virbac 76 
Limited, Bury St Edmunds, UK) has been found to be useful anecdotally, did not 77 
seem to result in detectable levels of drug in the blood14 and may only have a weak 78 
skin-thinning effect compared to other glucocorticoids.15 There are few data 79 
regarding the efficacy of antihistamines in the management of equine allergic skin 80 
disease. Antihistamines used in horses include hydroxyzine and diphenhydramine, 81 
with anecdotal reports of greater benefit in urticaria than pruritus;9 cetirizine was 82 
shown to be ineffective in the management of IBH.16 Systemic glucocorticoids are 83 
often required in horses with atopic dermatitis to control pruritus and limit self-trauma. 84 
Injectable or oral dexamethasone and oral prednisolone are the most commonly 85 
recommended, with long-term therapy aiming at lowest necessary doses given on 86 
alternate days.9 87 
For allergen-specific immunotherapy (ASIT), allergen-specific IgE can be detected by 88 
intradermal testing (IDT) and serological methods.3,7,17-21 However, results from IDT, 89 
considered to be the gold standard test, and from serological tests correlated poorly 90 
or not at all in two equine studies.17,20 Positive IDT reactions may occur in normal 91 
horses, but atopic horses show more numerous and stronger positive reactions.3,22 A 92 
few studies have evaluated the efficacy of ASIT in equine atopic dermatitis. Most 93 
authors report a 60-71% good to excellent response to ASIT based on the results of 94 
intradermal testing,1,4,8,23 but higher response rates have also been described. In one 95 
study, 13 of 15 horses with urticaria showed an excellent response to immunotherapy 96 
after one year.24 In a placebo-controlled study of 28 horses with insect and 97 
environmental hypersensitivities, 64% of the horses treated with ASIT showed a 50% 98 
or greater improvement compared to 23% with placebo,25 but more recently an 99 
overall response rate of 84%, as perceived by the owners, was reported in a large 100 
retrospective study.8 However, of those where glucocorticoids could be discontinued, 101 
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59% were well controlled with ASIT as the sole treatment and 9% of the partial 102 
responders needed doxepin in addition to ASIT. In 44% of cases, ASIT was 103 
discontinued due to resolution of clinical signs, with two thirds of these reporting no 104 
recurrence of disease, but recurrence of clinical signs occurred within 1-12 years of 105 
stopping ASIT in the remaining one third.  106 
The aims of this study were to investigate the progression of atopic dermatitis in 107 
horses after IDT and to summarise their IDT results. Owners’ perceptions and reports 108 
on their horses’ skin disease, on medical treatment utilised and on effects of 109 
management changes over time were investigated through telephone questionnaires. 110 
Methods 111 
The study had been approved by the Royal Veterinary College Ethics and Welfare 112 
committee (R349). 113 
Study population 114 
Horses with suspected atopic dermatitis which had been referred for intradermal 115 
testing to one of two dermatology referral centres in the South East of England 116 
between 2006 and 2011 were enrolled. Patients had been diagnosed initially with 117 
allergic skin disease by their referring veterinary surgeon. At referral, allergic 118 
dermatitis was confirmed clinically based on a history and presenting signs of pruritus 119 
and/or urticaria after ectoparasite infestations and microbial infections had been ruled 120 
out. Dermatological examination was performed combined with microscopic 121 
examination of skin scrapings, coat brushings and/or with anti-ectoparasite therapy, 122 
cytological examination of lesions, and fungal or bacterial culture or antimicrobial 123 
therapy when indicated. Insect-bite hypersensitivities were ruled out by confirming 124 
non-summer seasonal or perennial disease from the medical records. Food 125 
hypersensitivity was discussed with every owner and elimination diet trials 126 
recommended but IDT was performed irrespectively, based on suspected atopic 127 
dermatitis. 128 
Information on signalment (age, sex, breed or type), cutaneous signs relevant for 129 
referral for IDT (pruritus, urticaria, both, seasonality), previous therapy including 130 
response (glucocorticoids, antihistamines) and elimination diet trials was collected 131 
from electronic or paper medical histories as far as available. 132 
Intradermal testing 133 
All horses were tested using procedures as previously described6 against allergens 134 
considered relevant for allergic skin disease in Europe such as environmental mites, 135 
epithelia including feathers, and pollens (grasses, weeds and flowers, trees). In 136 
addition, allergen solutions of insects, fungi, grain crop pollens, house dust and grain 137 
mill dust and smut were included when available. Allergen test kits varied minimally 138 
in their composition over the six-year duration of the study due to availability of 139 
allergen solutions and between referral centres. Allergens used were recorded for 140 
each horse from the medical records. Allergen solutions had been sourced over time 141 
from one of two manufacturers (Greer Laboratories, Lenoir, North Carolina, U.S.A. or 142 
ArtuVet, Lelystad, Netherlands) with concentrations and dilutions available in the 143 
supplementary table (Supplementary table S1). 144 
Reactions were considered positive if the diameter of the wheal was greater than the 145 
mean of the positive and negative controls measured at 30 minutes. Wheal sizes 146 
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were assessed at 30 minutes and 2-4 hours (considered immediate and late-phase 147 
IgE-mediated reactions). Additional observations were made at 12-24 hours to 148 
assess delayed reactions. ASIT was offered for all horses showing positive reactions 149 
to allergens suitable for inclusion (indoor allergens, epithelia, pollens) but not for 150 
horses only showing reactions to fungi and insects. 151 
Management changes were recommended for all horses, depending on groups of 152 
allergens implicated by IDT (indoor allergens and dusts, epithelia, pollens, insects), 153 
to reduce exposure (Supplementary tables S1, S2). At Veterinary Dermatology 154 
Referrals, specific changes recommended included use of rubber matting in stables 155 
with minimal or no loose bedding, feeding of vacuum-packed, wilted grass products 156 
to replace hay and feeding of pelleted concentrate foods stored for only short periods 157 
in original packaging, frequent rug laundering and quarterly pressure cleaning of 158 
stables, removal of bird nests and use of selective weed killer, if relevant.  159 
Owner recruitment 160 
Owners were telephoned between September 2013 and March 2014 and asked for 161 
their participation in a telephone questionnaire study on their horse’s skin disease, 162 
medication, effect of allergen-specific immunotherapy (ASIT) and implementation of 163 
management changes since IDT. Owners were called from known telephone 164 
numbers (number not withheld by the caller) by the same investigator (DH) up to 165 
three times if there was no reply and no answering machine and up to two messages 166 
were left on answering machines before the case was excluded due to failed contact.  167 
Owners of horses who were known to be dead since IDT were not contacted. For 168 
horses reported deceased by their owner during the telephone contact, the cause of 169 
death was recorded, but they were not asked to complete the questionnaire. 170 
Questionnaires 171 
Questions were divided into three broad topics. Firstly, owners were asked to assess 172 
their horse’s skin problem at the time of the telephone questionnaire and at the time 173 
of IDT. They were asked to describe skin signs as pruritic, urticarial, both or other, 174 
whether changes in type or distribution of problems had been observed since IDT 175 
and whether other skin problems had been diagnosed by their veterinarian since IDT. 176 
Owners were asked to assess the severity of itching and/or urticaria on analogue 177 
scales of 0-10 (0 for normal/never and 10 for severe/present all the time). 178 
Secondly, questions on medication and other treatments, specifically glucocorticoids, 179 
antihistamines, ASIT, antidepressants, nutritional supplements and washes, were 180 
asked. Sub-questions for each treatment were whether the horse had ever received 181 
it, was currently receiving it and how frequently (seasonally, throughout the year), 182 
whether the treatment was tolerated and whether the owner thought the treatment 183 
had improved skin problems.  184 
Thirdly, owners were asked about their horses’ current management and on 185 
implementation of management changes recommended at time of IDT 186 
(Supplementary information S2), including whether they had changed barn or 187 
paddock, where the horse spent most of its time, type of bedding used, rugging (type, 188 
time spent wearing rugs and frequency of laundering), clipping (frequency and 189 
extent) and ectoparasite and fly control measures. For each question, owners were 190 
asked whether they considered those changes beneficial to their horse’s skin 191 
problem.  192 
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An option to answer ‘unsure’ or ‘unknown’ was included where appropriate. The 193 
questionnaire was trialled in six pilot calls and adjusted based on feedback. Each 194 
questionnaire was estimated to take 20 minutes including a short introduction 195 
outlining the study purpose, confidentiality provisions and the option to decline. At the 196 
end of the questionnaires, owners were offered contact details of investigators.  197 
Data analysis  198 
Microsoft Excel (Microsoft, version 15.38, 2017) was used for data collection and 199 
analysis.  200 
Results 201 
Enrolled horses and owners 202 
Eighty-two horses had undergone IDT for suspected atopic dermatitis during the 203 
study period, 15 from the RVC, 67 from Veterinary Dermatology Referrals (original 204 
starting population). Ages at time of IDT ranged between one and 25 years (mean 205 
9.9 years). There were 40 mares, 40 geldings, one stallion and one horse of 206 
unknown sex. Breeds or types varied, with 23 recorded as cob or pony, mostly Welsh 207 
cob, 21 as thoroughbred including thoroughbred crosses, 7 Irish sports horses, 8 208 
warmbloods and 23 other types. Pruritus was the presenting complaint in 36 horses 209 
(43.9%), urticaria in 34 horses (41.5%) and 12 (14.6%) presented with both. In most 210 
horses (67/82, 81.7%), lesions were reported as generalised. Of the 15 horses with 211 
localised lesions, eight showed signs only on the trunk, six on the head and one on 212 
the legs. All animals suffered from skin disease during the winter months but 19 213 
(23.2%) showed seasonal flares during spring or summer. 214 
Owners of 61 (74.4%) horses were contacted by telephone. For the remainder, either 215 
contact details were not available or attempts to make contact as described above 216 
had failed. One owner declined participation and two could not provide answers as 217 
the horses had been sold soon after IDT. The time between IDT and telephone 218 
questionnaire for the 58 horses ranged between 28 and 88 months (mean 71 months 219 
or 5.9 years).  220 
At the time of telephone contact, eleven of the 58 (19.0%) horses were reported 221 
dead, including four (6.9%) euthanised due to uncontrollable skin disease (three with 222 
pruritus, one with urticaria). One had died a spontaneous death of unconfirmed 223 
cause, five had been euthanised for known diagnoses (brain tumour, lymphoma, 224 
colic, lameness (investigated and confirmed as non-laminitic), kissing spines) and 225 
one horse for old age-related reasons. 226 
Intradermal tests 227 
The average number of allergens each horse was tested against was 54.2 (standard 228 
deviation (SD) 10) and the average number of positive reactions per horse was 13 229 
(SD 8.1). Two horses had shown no positive wheal and flare reactions to any of the 230 
allergens despite strong histamine injection reaction. The allergens tested in at least 231 
50 horses and which resulted in positive reactions in at least 25% of horses are listed 232 
in Table 1. Most (1247, 96.1%) of the 1297 positive reactions recorded in total 233 
occurred at the early readings considered compatible with immediate and late-phase 234 
hypersensitivity reactions. At the later time points, compatible with delayed reactions, 235 
122 (9.4%) positive reactions were recorded, 72 at sites of earlier readings, 50 236 
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(3.9%), distributed over all allergen groups, that had not been recorded at earlier time 237 
points. 238 
Skin disease - owner assessment 239 
Of the 47 horses for which follow up information was available, (14 RVC, 33 240 
Veterinary Dermatology Referrals), owners considered their horse’s skin disease at 241 
the time of telephone contact as resolved without medication in 18 cases (38.3%), as 242 
improved with treatment in 25 cases (53.2%) and as unchanged or worse despite 243 
medication in four cases (8.5%). Six of the 18 horses that no longer had skin 244 
problems at the time of telephone contact had been lesion-free since the time of IDT 245 
while another ten had not had skin disease for at least the previous two years. Four 246 
of these horses had had management changes implemented after IDT (see below) 247 
and two further horses only showed skin disease after known triggers (cereal-based 248 
food or treats, shavings). The remaining 29 horses were still receiving either 249 
glucocorticoids or antihistamines throughout the year or at least three times a year 250 
during flares. Six owners reported that their horses had been diagnosed with pituitary 251 
pars intermedia dysfunction since IDT and that new, different skin lesions had 252 
developed (crusting papules, urticaria in previously pruritic horses and vice versa).  253 
Owners’ assessment of pruritus, irrespective of medication or management used, on 254 
a 1-10 scale gave a median of 9 (range 3-10) at the time of IDT and of 1.5 (range 0-255 
6) at the time of telephone contact. Median scores for the frequency of urticaria flares 256 
were 8 (range 2-10) at the time of IDT and 2 (range 0-7) at telephone contact. 257 
Medication and immunotherapy - owner assessment 258 
Systemic glucocorticoids had been used in 35/47 horses (74.5%) to control skin 259 
disease since IDT, including seven still receiving treatment at the time of telephone 260 
contact. Good response to glucocorticoid therapy was reported in 94.3% of horses 261 
(33/35) after IDT. Adverse effects of glucocorticoid therapy were reported by owners 262 
in 7/35 (20%) including laminitis in one heavy draft horse (which according to the 263 
medical records was recorded as a foot abscess and without further mention of 264 
laminitis in the medical records during the subsequent two years), two horses with 265 
flares of pre-existing laminitis, and one each with drowsiness, weight gain, or 266 
behaviour changes.  267 
Twelve owners reported using topical glucocorticoid preparations (hydrocortisone 268 
aceponate spray (Cortavance): n=6, fusidic acid/bethamethasone combination 269 
(Fuciderm, now Isaderm, Dechra Veterinary Products, Shrewsbury, UK): n=4, 270 
unknown human eczema cream: n=1), and all but one owner observed a beneficial 271 
effect when the product was applied at least daily.   272 
Twenty-eight horses (59.6%) had received antihistamines (type unknown) at some 273 
stage since IDT to control their cutaneous signs and good response was reported in 274 
17 of these 28 horses (60.7%). Eight horses were still maintained on antihistamines 275 
as the sole medication at the time of telephone contact. Drowsiness was the only 276 
adverse effect reported in three horses. 277 
ASIT had been ordered for 27 horses (57.5%) but its use was only reported by 278 
owners of 14/47 horses (29.8%) with nine owners of these 14 horses (64.3%) 279 
reporting a beneficial effect including eight reporting a 75-100% improvement. In only 280 
three horses was immunotherapy continued beyond the first prescribed 281 
 
 
 
 
8 
immunotherapy vial of at least nine months; in one of them antihistamines were given 282 
concurrently throughout. A further two horses were restarted on ASIT when clinical 283 
signs relapsed after immunotherapy had been discontinued following completion of 284 
injections with the initial vial. Restarting ASIT was perceived as helpful again in both 285 
cases. The remaining nine horses no longer received ASIT at the time of telephone 286 
contact. Six owners stated they thought they had finished the treatment after the 287 
initial vial (typically nine months), including three in which treatment was thought to 288 
have had no effect. Another two owners stopped ASIT before completing the initial 289 
vial due to lack of effect and one owner stated expense as the reason for stopping. 290 
Twelve owners reported administering the maintenance injections themselves 291 
(injections by the veterinarian as default administration type). No systemic adverse 292 
effects were reported, localised injection site reactions were seen by owners in 6/14 293 
horses (42.9%) on individual occasions, none persisted or required veterinary 294 
attention. 295 
Fly prevention was used in 22 (46.8%) horses regularly during the spring and 296 
summer. In total, 38 horses (82.1%) were receiving or had received other agents with 297 
the aim to control their skin disease since IDT. These included systemic antimicrobial 298 
therapy (n=1), shampoo therapy used at least weekly (n=18) with seven owners 299 
using chlorhexidine-based products, and 11 using products of unknown composition 300 
but with claims of alleviating allergic skin signs (and 12/38 owners (31.6%) perceiving 301 
a beneficial effect). Skin-related, non-prescription food supplements (various, 302 
unknown) had been given by 30 owners (65.2%) without adverse effects reported. 303 
Management changes  304 
Twenty-two owners (46.8%) had implemented recommended changes to stables, 305 
bedding, feed or rugs, and nine of those (40.9%) reported a perceived subsequent 306 
improvement in their horse’s skin disease, including four horses for which no 307 
additional medication had been needed since. Skin disease was reported to have 308 
improved in three horses after they had been relocated to a different yard, in another 309 
three following dietary changes (treats removed from diet), one horse improved when 310 
shavings were removed from its stable, and in the remaining two horses multiple 311 
changes had been made concurrently.  312 
Almost all horses (45, 97.8%) were reported to wear rugs at some time during the 313 
year with 34 wearing the rug all day during the cooler months. Thirty-five of 47 314 
(74.5%) horses were regularly clipped.  315 
Discussion 316 
This is the first study to report on the management of atopic horses over time, and a 317 
reporting interval greater than two years was available for all. While information 318 
derived from owner interviews was collected retrospectively and is inevitably 319 
associated with a high degree of subjectivity, it still provides a realistic insight into the 320 
burden of allergic skin disease on horses and their owners, and may help to stimulate 321 
future research and improvements in clinical management. In addition, questionnaire 322 
data were collected during the colder months of the year in the UK which may have 323 
biased reporting. However, in the UK, clinical signs and onset of atopic dermatitis in 324 
the horse have been reported throughout the year,2 and including onset and 325 
exacerbation in autumn, suggesting that the impact of seasonality may be less 326 
relevant. 327 
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The data on clinical signs and IDT results collected from medical records were 328 
broadly in line with similar previously published work,8,16 including one study in the 329 
South of England.6 Positive reactions to house dust mites, storage mites and insects 330 
predominated, likely reflecting exposure to such allergens through a largely stabled 331 
lifestyle and management, including frequent use of house dust mite-harbouring 332 
rugs,26 and exposure to biting insects when at pasture.  333 
Results from this study on disease outcome at least two years after referral were 334 
highly surprising, firstly with regard to the substantial proportion of horses for which 335 
owners reported that skin disease had resolved and treatment had not been required 336 
for at least two years and secondly, with regard to the number of deceased horses.  337 
These findings challenge the widely accepted anecdotal belief that atopic dermatitis 338 
in the horse is chronic and requires lifelong treatment.5,7,9 Unfortunately, our data do 339 
not allow conclusions to be made on duration of disease before resolution in these 340 
horses, and so predictions cannot be made on how long signs might persist in horses 341 
with potentially transient presentations. However, the results suggest that, at least in 342 
some horses, the prognosis for atopic dermatitis can be excellent and they further 343 
corroborate previous advice that it is best to perform allergen tests if the disease is 344 
recurrent or persistent for more than six to eight weeks.27 Whether resolution of skin 345 
signs without medication was spontaneous or due to management changes, which 346 
were perceived to help by almost half of the owners, remains unknown. The role of 347 
allergen load rather than exposure is less clear for atopic dermatitis compared to 348 
respiratory lower airway disease in the horse.28 However, in the absence of such 349 
data, the benign nature of recommendations on management changes warrant 350 
inclusion in the management plan for every atopic horse presented for IDT. 351 
In contrast, the finding that 19% of horses were dead at the time of telephone 352 
interview, including 7% (four horses) where owners reported that the animals had 353 
been euthanised due to uncontrollable skin disease, is concerning. While research 354 
on the pathomechanisms and treatment options on allergic diseases has progressed 355 
substantially over the past decades, the social implications of chronic allergic 356 
diseases are only slowly starting to receive attention. Initial results of a survey on 357 
health-related quality of life in atopic dogs and on quality of life in their owners 358 
showed that the disease had a deeply negative impact on both measures but only 359 
1% of owners stated they had contemplated euthanasia.29 In addition, treatment was 360 
considered a major financial burden by a third of dog owners and 40% stated that 361 
they had to limit other expenses as a consequence. The questionnaire in our study 362 
was not designed to further explore reasons for euthanasia but the results are likely 363 
to reflect some degree of welfare concerns, implications on the use of a horse with 364 
skin disease and the financial burden associated with chronic skin disease. Other 365 
horse-specific factors may also have played a role and need to be investigated 366 
further.  367 
Of the 29 horses for which management of skin disease was still required after IDT, 368 
different combinations of antihistamines, glucocorticoids, ASIT and management 369 
changes were reported to achieve acceptable levels of control with tolerable adverse 370 
effects for most patients and owners. Results on drug efficacy need to be interpreted 371 
with care as these were based on owner impressions over time rather than on 372 
veterinary assessment following a defined intervention period. However, the high 373 
frequencies of beneficial effects reported for glucocorticoids (94.3%), mainly as oral 374 
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prednisolone, and for antihistamines (60.7%) provide some assurance on treatment 375 
effect. To date, despite their wide use, only review articles describe the use of both 376 
medications in the treatment of allergic skin disease in horses and provide some 377 
pharmacokinetic information and dose recommendations.9,23 Further study is needed 378 
on which therapies or combinations help atopic horses most and if there is a 379 
difference in response to therapies between pruritic and urticarial horses which was 380 
not the focus of this study. Slightly more information is available on the use of 381 
glucocorticoids for non-infectious lower airway disease where inflammation is thought 382 
to contribute to clinical signs.28 Concerns over glucocorticoid use as a risk factor in 383 
the development of laminitis are widespread, but the scientific basis for this 384 
association is sparse, at least for non-predisposed horses.30-32 Results from two 385 
recent studies seem to show that such a link may have been overestimated,33,34 but 386 
due to the critical consequences of laminitis, further research is still needed. In light 387 
of the relatively high number of atopic horses in this study which were euthanised 388 
due to uncontrolled disease, and none due to laminitis caused by glucocorticoid 389 
therapy, concerns over the potential risk of laminitis need to be balanced 390 
against welfare considerations due to uncontrolled atopic dermatitis. In the authors’ 391 
opinion, glucocorticoids have an important role to play in the management of atopic 392 
horses, and prednisolone at low doses given on alternate days to horses not 393 
predisposed to laminitis would be a recommended strategy.9  394 
The benefit of ASIT reported in 64% of horses in this study was lower than the 84% 395 
owner-reported efficacy from a recent North American study on 41 horses receiving 396 
ASIT,8 but comparable to those found by Rosenkrantz et al. in horses.25 However, 397 
the low uptake of ASIT following IDT in this study was surprising and disappointing. 398 
Reasons for not starting or at least not pursuing therapy were not explored as these 399 
findings had been unexpected. Measures have been taken since to extend 400 
discussion with owners and strengthen recommendations towards ASIT. 401 
While “much folklore still remains in respect of certain equine skin diseases” as 402 
stated in 1970 by the late L.R. Thomsett,35 the results from this study on long-term 403 
management of allergic horses from an owner perspective indicate that atopic 404 
dermatitis may have a better prognosis than in other companion animals and may not 405 
always be chronic. Still of concern though, the high number of euthanised horses in 406 
this study suggests that severe cases may be difficult to control and that the burden 407 
of chronic skin disease for owners should not be underestimated. Management 408 
changes, following identification of relevant allergens by IDT, in combination with 409 
medication and sometimes ASIT, may help provide effective control of clinical signs.  410 
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Tables 507 
Table 1. Allergens tested in at least 50 of the 82 horses and resulting in positive 508 
reactions in 25% or more of horses 509 
Allergen No. of 
positive 
reactions / 
horses tested 
% 
Positive 
Kit (Greer 
Laboratories 
or Artu 
Biologicals) 
Dermatophagoides farinae (farina mite) 76/85 89.4 Both 
Dermatophagoides pteronyssinus (house 
dust mite) 74/85 87.1 Both 
Moth 55/65 84.6 Greer 
Aedes communis (mosquito) 45/65 69.2 Greer 
Tyrophagus putrescentiae (copra mite) 53/78 68.0 Both 
Tabanid (horse fly) 43/65 66.2 Greer 
Lepidoglyphus destructor (hay mite) 52/84 61.9 Both 
Acarus siro (flour mite) 51/85 60.0 Both 
Grain mill dust 39/65 60.0 Greer 
Culicoides (midge) 34/64 53.1 Greer 
Trifolium pratense (red clover) 43/84 51.2 Both 
Grain mill smut 33/65 50.8 Greer 
Mixed feathers (chicken, goose, duck) 42/84 50.0 Both 
Urtica dioica (stinging nettle) 32/64 50.0 Greer 
Cockroach, German 29/65 44.62 Greer 
Avena sativa (cultivated oat) 21/55 38.18 Greer 
Leucanthemum vulgare (daisy) 31/84 36.90 Both 
Rumex crispus (yellow dock) 23/64 35.94 Greer 
Soldiago virgaurea (golden rod) 30/84 35.71 Both 
Taraxacum officinale (common dandelion) 22/62 35.48 Both 
Sheep epithelia 22/63 34.92 Greer 
Salix viminalis (pussy / black willow) 22/64 34.38 Greer 
Aspergillus fumigatus 22/64 34.38 Greer 
Artemisia vulgaris (common mugwort) 23/84 27.38 Both 
Rhizopus nigricans 14/55 25.45 Greer 
Note: House dust and black ant also showed reactions in 71.5% and 70%, 510 
respectively, but were only tested in 14 and in 30 horses, respectively. 511 
  512 
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S1: Supplementary table 1: Allergen solutions and dilutions used for intradermal 513 
testing of horses during the study period 514 
 
 
Allergen 
Dilutions Greer 
from 20.000 PNU 
stock solutions up 
to 2008 
Dilutions Greer 
from 20.000 PNU 
stock solutions from 
2008 
Dilution Artu 
Controls Histamine phosphate  1:10000 w/v 1:10000 w/v 0.1 mg/ml 
Saline n/a n/a n/a 
Indoor 
allergens and 
dusts 
Dermatophagoides farina (farina mite) 1:10 1:10 100 NU/ml 
D. pteronyssinus (house dust mite) 1:1000 w/v 1:1000 w/v 100 NU/ml 
Acarus siro (flour mite) 1:20 1:20 100 NU/ml 
Tyrophagus putrescentiae (copra mite) 1:20 1:20 100 NU/ml 
Lepidoglyphus destructor (hay mite) 1:20 1:20 100 NU/ml 
Euroglyphus maynai n/i n/i 100 NU/ml 
House dust  1:20  n/i n/i 
Grain mill dust 1:20 1:20 n/i 
Grain mill smut 1:1000 w/v 1:1000 w/v n/i 
Epithelia Horse dander n/i 1:20 n/i 
Dog epithelium n/i  100 µg/ml 
Mouse dander n/i 1:20  
Cat dander (Felis domesticus) 1:20 1:20 100 µg/ml 
Mixed feathers (chicken, goose, duck) 1:20 1:20  
Duck feathers (Anas platyrhynca) n/i n/i 100 µg/ml 
Goose feathers (Anas anser) n/i n/i 100 µg/ml 
Chicken feathers (Pullus gallinaceus) n/i n/i 100 µg/ml 
Sheep epithelia 1:20 1:20  
Epithelial mix 1 (guinea pig, dog, cat, hamster, 
rabbit) 
n/i n/i 100 µg/ml 
Grass 
pollens 
Kentucky blue (meadow) grass (Poa pratensis) 1:20 1:20 1000 NU/ml 
Red top (bent grass, Agrotis gigantean) 1:20 1:20 1000 NU/ml 
Couch grass 1:20 1:20 n/i 
Orchard grass (cocksfoot, Dactylis glomerata) 1:20 1:20 1000 NU/ml 
Sweet vernal (Anthoxanthum odoratum) 1:20 1:20 1000 NU/ml 
Velvet grass (Yorkshire fog, Holcus lanatus) 1:20 1:20 1000 NU/ml 
Timothy (Pheleum pratense) 1:20 1:20 1000 NU/ml 
Meadow fescue (Festuca pratensis) 1:20 1:20 1000 NU/ml 
Perennial rye grass (Lolium perenne) 1:20 1:20 1000 NU/ml 
Couch grass 1:20 1:20 n/i 
Brome grass 1:20 n/i n/i 
Avena sativa (cultivated oat) n/i n/i 1000 NU/ml 
Bermuda grass (Cynodon dactylon) n/i n/i 1000 NU/ml 
Grass pollen mixture (Bermuda, orchard, 
sweet vernal, Timothy, velvet) 
n/i n/i 1000 NU/ml 
Weed 
pollens 
Sheep sorrel (Rumex acetosella) 1:20 1:20 1000 NU/ml 
Ragweed (Ambrosia elatior) n/i 1:20 1000 NU/ml 
Golden rod (Soldiago virgaurea) n/i 1:20 1000 NU/ml 
Yellow dock (Rumex crispus) 1:20 1:20 n/i 
Common dandelion (Taraxacum officinale) 1:20 1:20 1000 NU/ml 
Red clover (Trifolium pratense) 1:20 1:20 1000 NU/ml 
Common mugwort (Artemisia vulgaris) 1:20 1:20 1000 NU/ml 
Daisy (Leucanthemum vulgare) 1:20 1:20 1000 NU/ml 
Stinging nettle (Urtica diodica) 1:20 1:20  
English plantain (Plantago laceolata) 1:20 1:20 1000 NU/ml 
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Lamb's quarter (Chenopodium album) 1:20 1:20 1000 NU/ml 
Weed pollen mixture 1 (mugwort and nettle) n/i n/i 1000 NU/ml 
Weed pollen mixture 2 (mugwort, nettle, 
dandelion, plantain) 
n/i n/i 1000 NU/ml 
Tree pollens Alder (Sambucus nigra) n/i 1:20 1000 NU/ml 
American elm n/i 1:20 n/i 
Red oak 1:20 1:20 n/i 
Black/pussy willow (Salix viminalis) n/i 1:20 n/i 
American beech (Fagus sylvatica) 1:20 1:20 1000 NU/ml 
Eastern sycamore (Plantanus occidentalis) 1:20 1:20 1000 NU/ml 
White poplar 1:20 1:20 n/i 
White ash 1:20 1:20 n/i 
American hazelnut (Corylus avellana) n/i 1:20 1000 NU/ml 
White birch (Betule pendula) 1:20 1:20 1000 NU/ml 
Horse chestnut (Buckeye, Aesculus 
hippocastanum) 
n/i n/i 1000 NU/ml 
Hawthorn (Crataegus) n/i n/i 1000 NU/ml 
Linden (Tilia cordata) n/i n/i 1000 NU/ml 
Tree pollen mix 1 (birch, alder, hazel) n/i n/i 1000 NU/ml 
Tree pollen mix 2 (English oak, European 
beech, American elm) 
n/i n/i 1000 NU/ml 
Moulds & 
fungi 
Aspergillus fumigatus 1:20 1:20 n/i 
Aureobasidium pullulans 1:20 1:20 n/i 
Alternaria alternata 1:20 1:20 n/i 
Phoma beta 1:20 1:20 n/i 
Penicillium notatum 1:20 1:20 n/i 
Cladosporium herbarium 1:20 1:20 n/i 
Fusarium moniliforme 1:20 1:20 n/i 
Mucor racemosus 1:20 1:20 n/i 
Rhizopus nigricans 1:20 1:20 n/i 
Trichoderma spp. 1:20 1:20 n/i 
Malassezia pachydermatis 1:20 1:20 n/i 
Fungus mixture 1 (Alternaria alternate, 
Aspergillus fumigatus, Cladosporium 
herbarum) 
n/i n/i 100 ng/ml 
Insects Flea (Ctenocephalides spp.) 1:1000 w/v 1:10 1000 NU/ml 
Cockroach, German n/i 1:20 n/i 
Horse fly (Tabanus spp.) 1:20 1:20 n/i 
Moth 1:40 1:40 n/i 
Aedes communis (mosquito) 1:20 1:20 n/i 
Culicoides (midge) 1:5 1:5 n/i 
Culicoides (midge) 1:10 1:10 n/i 
House fly 1:20 n/i n/i 
Black ant 1:20 n/i n/i 
n/i: not included. NU: nitrogen unit 515 
 516 
  517 
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Supplementary table 2: Suggestions on management changes provided to horse 518 
owners to reduce exposure to environmental mites in atopic horses. Owners were 519 
informed that recommendations were based on anecdote rather than evidence for 520 
efficacy and that measures should be tailored to each horse depending on practicality 521 
and intradermal test result 522 
Stable Foodstuff Rugs Other 
Replace loose 
bedding with 
rubber matting 
Storage in clean, 
sealed 
containers 
Avoid excessive 
rugging 
Maintain horse at 
pasture for 
extended periods 
Quarterly 
vacuuming and 
pressure hosing 
of stable walls, 
ceiling, floor 
Replace hay with 
wilted, vacuum-
packed grass 
products 
Launder rugs 
frequently at high 
temperatures or 
freeze for 2-3 days 
after laundry 
Use of broad-leaf 
weed-killer 
Reduce 
exposure to birds 
and poultry 
(remove nests 
before eggs are 
laid) 
Replace loose 
with cubed 
concentrate  
Add human anti-
allergy duvets (in 
polycotton cover) 
between skin and 
rugs to provide a 
barrier to dust mite 
allergens 
Insect prophylaxis 
with frequent 
applications of 
permethrin-
containing products 
as per data sheet or 
manufacturer’s 
recommendations 
 523 
 524 
